Treatment Experience of Pelvic Osteosarcoma Arising in Li-Fraumeni Syndrome

• Eiji Kozawa

  Department of Orthopedic Surgery, Nagoya Memorial Hospital, Nagoya, 468-8520, Japan

• Kenji Ina

  Palliative Care Team, Nagoya Memorial Foundation, Nagoya, 468-8520, Japan and Department of Geriatric Medicine, Shinseikai Dai-ichi Hospital, Nagoya, 468-0031, Japan

• Yuko Kato

  Palliative Care Team, Nagoya Memorial Foundation, Nagoya, 468-8520, Japan and Medical Social Work Consultation Room, Nagoya Memorial Hospital, Nagoya, 468-8520, Japan

• Atsushi Morizane

  HOSPY Renal Dialysis Division, Clinical Engineering, Nagoya 468-0031, Japan

• Megumi Kabeya

  Palliative Care Team, Nagoya Memorial Foundation, Nagoya, 468-8520, Japan and Department of Phamacy, Nagoya Memorial Hospital, Nagoya, 468-8520, Japan

• Tomoko Nishio

  Department of Pathology, Nagoya Memorial Hospital, Nagoya, 468-8520, Japan

• Koki Shimizu

  Department of Orthopedic Surgery, Nagoya Memorial Hospital, Nagoya, 468-8520, Japan

• Akiko Fujita

  Department of Orthopedic Surgery, Nagoya Memorial Hospital, Nagoya, 468-8520, Japan

• Naohiro Osada

  Department of Orthopedic Surgery, Nagoya Memorial Hospital, Nagoya, 468-8520, Japan

• Masatake Tsunoda

  Department of Orthopedic Surgery, Nagoya Memorial Hospital, Nagoya, 468-8520, Japan

We report the case of a woman in her 20s who developed osteosarcoma in the right iliac bone with germline variants in the TP53 gene (TP53: c.220Y＞C). She was referred to a university hospital and imaging studies and biopsy led to a diagnosis of Li-Fraumeni syndrome. After she underwent proton-beam therapy combined with chemotherapy along with weekly hyperthermia, she had been referred to our institution for easier access since 20XX+6. She noticed ipsilateral gluteal pain and swelling in 20XX+8. Imaging and histopathology were consistent with recurrence of the pre-existing osteosarcoma. The palliative interventions enabled her to stay at home; however, her pain consequently exacerbated in 20XX+9. She was admitted emergently, and she died after several days.

[1] Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250(4985): 1233-1238.

[2] Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003; 21(3): 313-320.

[3] Schneider K, Zelley K, Nichols KE, et al. Li Fraumeni Syndrome. GeneReviews® [Internet], University of Washington, Seattle, 1999 [Updated 2013].

[4] Kumamoto T, Yamazaki F, Nakano Y, Tamura C, Tashiro S, Hattori H, et al.Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol 2021; 26: 2161-2178.

[5] Tsukushi S, Nakamura T, Sugaya J, Naka N, Kobayashi H, Okuma T, et al. Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group. Cancer Manag Res 2020; 12: 10017-10022.

[6] Toguchida J, Yamaguchi T, Dayton SH, et al: Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992; 326: 1301-1308.

[7] McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, Thomas DM, Mitchell G. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 2014; 11(5): 260-71.

[8] Funato M, Tsunematsu Y, Yamazaki F, et al. Characteristics of Li-Fraumeni syndrome in Japan: A review study by the special committee of JSHT. Cancer Sci 2021; 112: 2821-34.

[9] Bougeard G, Renaux-Petel M, Flaman J-M, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers J Clin Oncol 2015; 33(21): 2345-52.

[10] Thariat J, Chevalier F, Orbach D, et al: Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes. Lancet Oncol 2021; 22: e562-e574

[11] Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48: 5358-62.

[12] Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian. National Comprehensive Cancer Network (NCCN). (2017) Website: www.nccn.org

[13] Kumamoto T. Cancer surveillance in patients with Li-Fraumeni syndrome Jap J Pediatric Hematology/Oncology 2019; 56(2): 118-125 (in Japanese).

[14] Villani A, Shore A, Wasserman JD, et al: Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11year follow-up of a prospective observational study. Lancet Oncol 17: 1295-1305, 2016.

[15] Ballinger ML, Best A, Mai PL, et al: Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: A meta-analysis. JAMA Oncol 2017; 3: 634-1639.

[16] Grasparil AD, 2nd, Gottumukkala RV, Greer MC, Gee MS. Whole-Body MRI Surveillance of Cancer Predisposition Syndromes: Current Best Practice Guidelines for Use, Performance, and Interpretation. AJR 2020; 215: 1002-1011.

[17] Barnett M, Breen KE, Kennedy JA, Hernandez M, Matsoukas K, MacGregor M. Psychosocial interventions and needs among individuals and families with Li-Fraumeni syndrome: A scoping review. Clin Genet 2022; 101(2): 161-182.

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.